JUDAS TRUDEAU HAS A CIGARETTE COMPANY MAKING VACCINES TO KEEP ALL CANADIANS ADDICTED TO TAKING VACCINE SHOTS EVERY MONTH.

JUDAS TRUDEAU HAS A CIGARETTE COMPANY MAKING VACCINES TO KEEP ALL CANADIANS ADDICTED TO TAKING VACCINE SHOTS EVERY MONTH.

DISEASES-ANIMAL TO HUMAN

REVELATION 6:7-8 (500 MILLION DEAD EACH FROM THE 4 JUDGEMENTS)(2 BILLION TOT DEAD HERE)
7 And when he had opened the fourth seal, I heard the voice of the fourth beast say, Come and see.
8 And I looked, and behold a pale horse:(CHLORES GREEN) and his name that sat on him was Death, and Hell followed with him. And power was given unto them over the fourth part of the earth,(2 billion) of (8 billion) to kill with sword,(WEAPONS)(500 million) and with hunger,(FAMINE)(500 million) and with death,(INCURABLE DISEASES)(500 million) and with the beasts of the earth.(ANIMAL TO HUMAN DISEASE)(500 million).

THE COVID-19 TOTALS.
WORLD OVER ALL CASES 487,214,831 - DEAD 6,162,962 - AS OF MON APR 04,2022-THESES ARE THE BLOOD TOTALS ON THE HEADS OF FAUCI-DRUG DEALERS MODERNA AND PFIZER. AND ALL THE LEADERS OF THE WORLD THAT SCAMMED THEIR CITIZENS TO TAKE THE POISON KILLER VACCINE SHOTS FOR THE CHILDREN SAKE AND THE EARTH OF COURSE.AS THE LIBBYDEMS PLAY ANY SIN GOES.

WELL JUDAS TRUDEAU OUT DONE HIMSELF THIS THIS. JUDAS TRUDEAU HAS GOT A CIGARRETTE COMPANY MAKING VACCINES FOR HIM. YES GET THE LITTLE USELESS EATING SLAVES OF CANADA ADDICTED TO TAKING VACCINES EVERY MONTH. BY THE CIGARETTE COMPANY PUTTING SOME ADDICTING METHOD RIGHT IN THE VACCINE. CIGARETTE COMPANIES ARE USED TO KEEPING PEOPLE ADDICTED TO THE STUFF THEY CREATE. WHAT A PERFECT WAY FOR JUDAS TRUDEAU TO KEEP ALL THE CANADIAN LITTLE SLAVES UNDER ADDICTION TO VACCINES. THATS WHY JUDAS TRUDEAU BOUGHT ENOUGH VACCINES FOR 10 VACCINE SHOTS FOR EVERY CANADIAN IN CANADA. CAN YOU SAY JUDAS TRUDEAU WANTS EVERYBODY ADDICTED TO TAKING VACCINE SHOTS EVERY MONTH. I FIGURE JUDAS TRUDEAU HAS BIG MONEY INVESTED IN THIS CIGARETTE VACCINE MAKING COMPANY. SO JUDAS CAN MAKE BILLIONS OF DOLLARS WHILE KILLING US CANADIANS OFF WITH VACCINE  SHOTS . THAT WE HAVE BEEN ADDICTED TO EVERY MONTH.

Why is WHO pushing back on a Health Canada–approved Medicago SARS-CoV-2 vaccine? Diana Duong and Lauren Vogel-CMAJ April 04, 2022 194 (13) E504-E505; DOI: https://doi.org/10.1503/cmaj.1095992

Health Canada approved Covifenz, the first Canadian SARS-CoV-2 vaccine, in February. But so far, Canada is the only country to do so, and a World Health Organization (WHO) official said it’s unlikely the vaccine will be approved for emergency use internationally because of the company’s links to the tobacco industry.Tobacco giant Phillip Morris International Inc. (PMI) owns a one-third equity stake in Medicago, the Quebec-based company that developed Covifenz with help from the federal government.The deal raised eyebrows among public health advocates, some of whom argue the government’s partnership with Medicago conflicts with Canada’s international commitments on tobacco control.Notably, Medicago was headed by PMI’s former vice-president of regulatory and scientific affairs when the federal government struck the deal to buy 76 million doses of the Covifenz vaccine in addition to investing $173 million in support.“It’s well known the WHO and the UN have a very strict policy regarding engagement with the tobacco and arms industry,” said Mariângela Simão, WHO’s assistant director-general for drug access, vaccines, and pharmaceuticals, in a media briefing. As such, “it’s very likely [Covifenz] won’t be accepted for emergency use listing.”A guidance document dated March 2 on the WHO website listed the vaccine as “not accepted.”Some experts have argued that approval of the vaccine would violate the spirit, if not the letter of the WHO Framework Convention on Tobacco Control (FCTC). Canada is one of 182 signatories to the treaty, which aims to protect public health policy-making from tobacco industry interference, among other goals.Guidelines on implementing the treaty state that governments should not “accept, support, or endorse partnerships” with the tobacco industry or “any entity or person working to further its interests.”“It’s imperative for countries to refrain from colluding and collaborating with tobacco companies,” said Les Hagen of the tobacco control advocacy group Action on Smoking and Health.He and others worry that even indirect partnerships may give the industry political leverage and a backdoor route to influence policy-makers.A 2018 review found that tobacco industry interference “continues to be the largest barrier to FCTC implementation worldwide.”Prior to the Medicago deal, Canada was regarded as a leader on tobacco control, ranking alongside New Zealand, Thailand, and India as a key proponent of the FCTC.Now, “not only are we seeing Big Tobacco getting into pharma and COVID-19 vaccines, but we are also seeing an act of collaboration with the federal government,” said Hagen.Canada defends Medicago partnershipWhile Health Canada publicly reports meetings with tobacco industry lobbyists, they do not report on meetings with Medicago. A federal spokesperson said this is because the department “has not held meetings with Medicago on matters related to tobacco control.”The spokesperson also noted that the Medicago deal is just one of more than $1.115 billion in investments that the government has made to establish or expand Canadian production facilities for vaccines and therapeutics on the advice of the COVID-19 Vaccine Task Force.According to Health Canada, the federal government is “compliant with its treaty obligations” because the FCTC specifically requires parties to protect against industry interference “with respect to tobacco control.” As the government sees it, that doesn’t preclude collaboration on ventures unrelated to tobacco, like vaccine procurement and development.The WHO and other organizations appear to take a different view. Medicago has reported difficulties getting a seat at WHO meetings alongside other pharmaceutical companies, and The Lancet allegedly declined to publish early research on the Covifenz vaccine.Tarik Jašarevic of the WHO said the organization disapproves of tobacco industry involvement in drug companies and “encourages Medicago to disengage from its links with PMI, which would allow WHO to be able to work with them like with other pharmaceutical companies.”According to the WHO, “there is a fundamental and irreconcilable conflict between the tobacco industry’s interests and public health policy interests.”For its part, Medicago says it is “committed to upholding and conducting business ethically and transparently.”A spokesperson told CMAJ that the company’s “top priority at the moment is to help fight the COVID-19 global pandemic,” and they are “grateful” for PMI’s investment.The spokesperson did not answer questions about how Medicago manages potential conflicts of interest, nor directly address concerns about its association with the tobacco industry, deferring to PMI for further comment.Both companies stressed that PMI currently holds a minority stake in Medicago and doesn’t control the company’s board of directors.A spokesperson for PMI’s Canadian subsidiary Rothmans, Benson & Hedges said the investment in Medicago is part of a broader strategy to “expand the business beyond tobacco and nicotine.”Health, science, technology, and sustainability are “at the heart of PMI’s future,” the spokesperson said. They did not answer how the company manages conflicts between those aims and tobacco business interests.-Big Tobacco rebrandingIt’s not the first time PMI has ventured into the health sector. Last year, the company acquired Fertin Pharma, which specializes in oral drug delivery systems, and Vectura, a British inhaler maker, ostensibly as part of the same move “beyond nicotine.”Some clinicians and scientists rallied against the latter acquisition, leading at least one major medical conference to cut ties with Vectura.According to Rothmans, Benson & Hedges, “our ambition is to replace cigarettes with science-based, smoke-free alternatives and eliminate smoking by 2035 or sooner.”David Hammond of the University of Waterloo said that tobacco companies have repeatedly claimed they would phase out conventional cigarettes going back to the 1950s — a claim that would be more credible if they weren’t still promoting the products and challenging tobacco control.“These claims are neither new nor are they compelling when you interpret them within their broader corporate actions,” Hammond said.Beyond concerns about industry interference in policy-making, some question the ethics of collaborating with companies that generate profit for an industry linked with more than eight million deaths each year. Canada alone spends billions of dollars annually on the direct health care costs of tobacco use.“If these companies want to reinvent themselves, they’ve got to stop selling cigarettes,” said Robert Schwartz, a professor of public health policy at the University of Toronto and executive director of the Ontario Tobacco Research Unit.Others are concerned that the incursion of Big Tobacco into vaccine manufacturing may undermine public trust in COVID-19 shots.Given the tobacco industry’s history of downplaying health harms, “these are companies with difficult paths in terms of respect for the public good,” said Chris MacDonald, an associate professor of business ethics at Ryerson University. “We are justified in not trusting them at this point, and we need to be able to trust vaccine companies.”Since Medicago signed the deal with the federal government, the company appears to be distancing from PMI. Takashi Nagao, a former executive of Mitsubishi Tanabe Pharma Corporation, has taken over as Medicago’s president and CEO from Bruce Clark, who was previously a PMI executive.PMI has also put out the word that it is seeking offers from investors who might be “better suited to help Medicago on the next phase of its journey.”This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/e-All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

WHO may reject Canadian-made Medicago COVID-19 vaccine because of ties to big tobacco-Mia Rabson-The Canadian Press Staff-Published Thursday, March 17, 2022 6:20PM EDT

OTTAWA -- Canada may not be able to donate millions of doses of the only COVID-19 vaccine made in the country because the World Health Organization is leaning against granting it an emergency-use licence.Medicago's two-dose Covifenz vaccine was authorized by Health Canada in February for adults 18 to 64. In clinical trials it was more than 70 per cent effective at preventing COVID-19 infections and 100 per cent effective against severe illness, prior to the Omicron wave.Medicago has also submitted an application to get their vaccine -- the only one in the world that uses vaccine-like particles grown in a plant -- approved by the World Health Organization.However, tobacco company Philip Morris owns about one-fifth of Medicago, and the WHO indicated Wednesday that the application was unlikely to proceed for that reason.Dr. Mariangela Sim+úo, WHO's assistant director general for drug access, vaccines and pharmaceuticals, said the WHO has strict policies about engaging with tobacco companies and arms manufacturers. As such, she said the review process for Medicago is on hold, and "it's very likely that it won't be accepted for the emergency-use licence."Medicago President Takashi Nagao said in a written statement that the company has not had an "official communication" from the WHO but stressed the issue is not related at all to the vaccine's safety or effectiveness.A WHO emergency-use licence is required for a vaccine to be used by the COVAX vaccine-sharing alliance, the main mechanism for helping get vaccines to people in countries that can't afford to buy them.If the WHO rejects Medicago's vaccine, Canada won't be able to donate any of its doses to the alliance, which is desperate for doses to reach its goal of vaccinating 70 per cent of people in every country by July.Canada has a contract for 20 million doses and an option for up to 56 million more, but Canada does not need them. More than 85 per cent of Canadians over the age of five are now fully vaccinated and going forward Canada is relying almost solely on the mRNA vaccines from Pfizer-BioNTech and Moderna.Canada had promised to donate any excess vaccines it purchased to COVAX-Canada could try to sign bilateral donation deals to donate Medicago but those are more time-consuming and many countries that need vaccines the most still rely on WHO approval processes rather than conducting their own.University of Ottawa law professor David Sweanor, who has made a career of going after tobacco companies in court, said it is "crazy" for the WHO to reject a perfectly good vaccine just to make a point about tobacco."We would rather have deaths by COVID in low- and middle-income countries, that would depend on approval by WHO, than a tobacco company GǪ even indirectly get any credit for having saved those lives," he said."And why are we mad at the tobacco companies? Because they've caused people to get sick and die. So how are we going to get even? We're going to cause people to get sick and die."Currently only one in 10 people in the world's poorest nations are fully vaccinated against COVID-19, and only one in seven have even one dose. In high-income countries, three in four people are fully vaccinated and half now have a third booster dose as well.The WHO has authorized 10 vaccines now for an emergency-use licence, including Pfizer, Moderna, Oxford-AstraZeneca and Johnson & Johnson.Health Minister Jean-Yves Duclos said Thursday he and Innovation Minister Francois-Philippe Champagne are following the process with the WHO very closely."Minister Champagne and I have contacted Medicago to make sure that its contact with WHO is done properly," he said.Canada invested $173 million in Medicago in 2020 to support development of the Covifenz vaccine and help Medicago expand its production facility in Quebec.Nagao confirmed Canada is currently Medicago's first and only customer, but he said there are ongoing discussions with others. Medicago has not said if it applied for approval anywhere else yet."We cannot comment further on these discussions as they are confidential," he said.On Thursday, Health Canada approved the use of Moderna's COVID-19 vaccine for children between the ages of six and 11 years old.The vaccine known as Spikevax had already been approved for those ages 12 and up. The pediatric version for children six to 11 is two 50-microgram doses. The vaccine for ages 12 and up is two 100-microgram doses.This report by The Canadian Press was first published March 17, 2022.